ArticleJournal of enzyme inhibition and medicinal chemistry2017
Design, synthesis and evaluation of
Article in Journal of enzyme inhibition and medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- Carbonic Anhydrase IX-Targeted Molecular Probe for Positron Emission Tomography Imaging of Clear Cell Renal Cell Carcinoma.Chemical & biomedical imaging · 2026Article
- Carbonic Anhydrase Inhibitors in Oncology.Sub-cellular biochemistry · 2026Review
- State of the art procedures towards reactive [EJNMMI radiopharmacy and chemistry · 2023Review
- Differential CMS-Related Expression of Cell Surface Carbonic Anhydrases IX and XII in Colorectal Cancer Models-Implications for Therapy.International journal of molecular sciences · 2023Article
- Advances in PET and MRI imaging of tumor hypoxia.Frontiers in medicine · 2023Review
- Design and synthesis of some new benzoylthioureido phenyl derivatives targeting carbonic anhydrase enzymes.Journal of enzyme inhibition and medicinal chemistry · 2022Article
- New Developments in Carbonic Anhydrase IX-Targeted Fluorescence and Nuclear Imaging Agents.International journal of molecular sciences · 2022Review
- Phosphonamidates are the first phosphorus-based zinc binding motif to show inhibition of β-class carbonic anhydrases from bacteria, fungi, and protozoa.Journal of enzyme inhibition and medicinal chemistry · 2020Article
- Copper-Mediated Late-stage Radiofluorination: Five Years of Impact on Pre-clinical and Clinical PET Imaging.Clinical and translational imaging · 2020Article
- Synthesis of high-molar-activity [Nature protocols · 2020Article
- Manual and automated Cu-mediated radiosynthesis of the PARP inhibitor [Nature protocols · 2020Article
- Experimental Carbonic Anhydrase Inhibitors for the Treatment of Hypoxic Tumors.Journal of experimental pharmacology · 2020Review
- Article
- Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.Scientific reports · 2019Article
- A Flexible Synthesis ofMolecules (Basel, Switzerland) · 2018Article
- Inhibition studies on a panel of human carbonic anhydrases with N1-substituted secondary sulfonamides incorporating thiazolinone or imidazolone-indole tails.Journal of enzyme inhibition and medicinal chemistry · 2018Article
- Automated synthesis of PET radiotracers by copper-mediatedJournal of labelled compounds & radiopharmaceuticals · 2018Article
- Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors.Metabolites · 2017Review
- Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX.Theranostics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbonic anhydrase IX (CA-IX) is a marker for tumor hypoxia, and its expression is negatively correlated with patient survival. CA-IX represents a potential target for eliminating hypoxic cancers. We synthesized fluorinated cationic sulfonamide inhibitors 1-3 designed to target CA-IX. The binding affinity for CA-IX ranged from 0.22 to 0.96 μM. We evaluated compound 2 as a diagnostic PET imaging agent. Compound 2 was radiolabeled with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.